Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iruplaltinib + pemetrexed
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Iruplaltinib + pemetrexed is a combination therapy being investigated for the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The combination consists of **iruplaltinib** (also known as iruplinalkib), a potent, oral, small-molecule tyrosine kinase inhibitor (TKI) that selectively targets ALK and ROS1 rearrangements, and **pemetrexed**, a standard-of-care antifolate chemotherapy agent. Iruplaltinib, developed by Qilu Pharmaceutical, works by inhibiting the phosphorylation of ALK and its downstream signaling pathways, which are critical for the survival and proliferation of ALK-positive tumor cells. Pemetrexed disrupts folate-dependent metabolic processes essential for DNA and RNA synthesis by inhibiting thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). This combination is specifically being evaluated in Phase 2 clinical trials as a neoadjuvant therapy for patients with resectable ALK-positive non-squamous NSCLC to improve surgical outcomes and long-term survival.
- Brand names
- AlimtaQixin'an
- Other names
- iruplinalkib + pemetrexed
02
Targets
GART (GAR transformylase)EGFR (Epidermal growth factor receptor)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)DHFR (Dihydrofolate reductase)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on iruplaltinib + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iruplaltinib + pemetrexed.